How is the post monoclonal antibodies (mAb) world going to develop in the future of biologics?

  As the pharma industry moves into the future of biologics production what challenges will they be facing? The field of biologics is currently on the brink of a new era of high tech drugs. These new drugs have been engineered to be more efficacious than typical mAbs by having a more targeted structure (i.e. antibody drug conjugates). Recently Amgen …

Protein A alternatives

The Protein A Debate: should we still be looking for alternatives?

Interest in researching a cost effective alternative to Protein A has waned in current years. Should we still be on the lookout for other methods of antibody extraction? Protein A is an essential but costly tool in the manufacture of most monoclonal antibodies (MAb). Protein A makes up approximately 30% of the total cost of production and in the past …

Download: Predicting quality and reliability: the implications of these factors on the selection of candidates for development

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Steffen Hartmann, Global Head Developability Assessment, Integrated …

Download: Daratumumab, a novel therapeutic human CD38 monoclonal antibody – a promising new treatment option in multiple myeloma

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Michael Karl Bauer, Senior Vice President of …

Download: Clinical Development of Tanibirumab, anti-KDR neutralizing fully human IgG

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Jin-San Yoo, President and CEO, PharmAbcine Inc,  who …

Download: Novel protease-resistant mAb platform engineered for use in anti-cancer and anti-microbial therapeutics

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Randall Brezski, Senior Scientist, Biotechnology Center of Excellence, …

antibodies

What are the antibodies to watch in 2014?

If you’re not sure, then Janice Reichert (Editor-in-Chief, mAbs Journal) has this covered. She’s written the handy report ‘Antibodies to watch in 2014‘ – this details all the monoclonal antibodies that are currently undergoing regulatory actions from the FDA and EMA, as well as details the  antibody therapeutics that are currently in Phase III trials. If you’re watching to see …

Download: State of the art analytical methods for antibodies, ADCs and bispecifics characterization

Download this presentation here > The European Antibody Congress  brings together big pharma, big biotech, SME Biotech, academia, regulators and the wider service provider community to discuss the latest R&D and advances in the antibody space – across mAbs, ADCs, bispecifics, multispecifics, and protein scaffolds. At the 2013 event, delegates were fortunate enough to hear from Dr Alain Beck (Senior Director, Antibody …

Download: Interviews with leaders in the antibody sector – the future of R&D in the antibody, ADC and bispecific space

There is undoubtedly a great deal of research going on within the antibody space, a significant number of therapeutics in the clinic and a lot of upcoming developments to watch out for. At the recent European Antibody Congress 2013, we took some time out to conduct some interviews with key members of the speaker faculty (you can view the full …

Top topics and companies in antibody clinical trials

In our recent European Antibody Congress Annual Survey we asked what the most topics are most important when it comes to mAb clinical trials. Below are the topics which came out on top; Novel target identification and validation Next generation of therapeutic anticancer mAbs Building a succesfull portfoloio of therapeutic mAbs Antibody Discovery – A Highly Integrated Approach Clinical update …